Autologous Conditioned Serum: Functional and Clinical Results

Autologous Conditioned Serum: Functional and Clinical Results Using a Novel Disease Modifying Agent for the Management of Knee Osteoarthritis

The purpose of this study was to investigate the potential ability of autologous conditioned serum (ACS) to decrease the pain and improve the joint functionality in patients affected by knee osteoarthritis (OA).

Fifteen patients with clinical and radiological signs of OA of the hip or knee were recruited for this study. Each patient received 4 injections of ACS (Orthokine®) at the site of OA once per week for 4 weeks. Clinical and functional evaluation were performed using VAS scale for pain, WOMAC scale and KSS functional and clinical scores before the first injection, at one week, at two weeks, at three weeks, at one month and at six months. Statistical analysis was done with the Wilcoxon Signed-Rank Test.

Inclusion Criteria:

• knee osteoarthritis >3 months in clinical and radiographic signs
• VAS for pain >50mm

Exclusion Criteria:

• Hepatitis B
• Hepatitis C
• HIV
• pregnancy
• drug abuse
• other intra-articular injections <6 months
• surgery on affected knee <12 months